Cargando…
Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition
In the current study we examined the combination of SAHA and SBE13 in cancer and non-cancer cells. HeLa cells displayed a synergistically reduced cell proliferation, which was much weaker in hTERT-RPE1 or NIH-3T3 cells. Cell cycle distribution differed in HeLa, hTERT-RPE1 and NIH-3T3 cells. SAHA-tre...
Autores principales: | Lange, Lisa, Hemmerich, Peter, Spänkuch, Birgit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694867/ https://www.ncbi.nlm.nih.gov/pubmed/26317649 |
Ejemplares similares
-
Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status
por: Lange, Lisa, et al.
Publicado: (2014) -
Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
por: Li, Mengyuan, et al.
Publicado: (2018) -
PLK1 inhibition-based combination therapies for cancer management
por: Su, Shengqin, et al.
Publicado: (2021) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016) -
PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy
por: Ruf, Stefanie, et al.
Publicado: (2017)